CSE:INNO - Post Discussion
Post by
Betteryear2 on Sep 03, 2024 9:28pm
Advances Liposomal CBD with Positive Response from FDA
HERZLIYA, Israel and CALGARY, Alberta, Sept. 3, 2024 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has received a positive response from the U.S. Food and Drug Administration (FDA) following Innocan's successful pre-Investigational New Drug (pre-IND) Type B meeting with the FDA held in July, for its lead drug product Liposomal Technology-CBD (LPT-CBD). Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting (newswire.ca)
Be the first to comment on this post